Home › Myelofibrosis › Kansas
Myelofibrosis clinical trials in Kansas
6 studies for Myelofibrosis are looking for participants at sites in Kansas.
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06661915A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- University of Kansas Medical Center, Kansas City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06343805Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
- The University of Kansas Cancer Center, Fairway
RecruitingEarly phase 1Healthy volunteers welcome
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT06414681A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- The University of Kansas Cancer Center, Westwood
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 17, 2026 · NCT06034002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Kansas Medical Center, Westwood
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- University of Kansas Cancer Center - Westwood, Westwood
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT06479135From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.